CD19 and acute lymphoblastic leukemia: No CAR-T-cell-related encephalopathy syndrome was observed, and all side effects were manageable.<h4>Conclusion</h4>Our report hints the feasibility and safety of CD19 CAR-T cell expressing membrane-bound IL-15 for patient with B-ALL even if relapsed after multiple CAR-T-cell therapies.